MAY 1·Stock Titan→
DBV Technologies (DBVT) ramps Viaskin Peanut spending with $229M cash runway
DBV Technologies (DBVT) reported a widened net loss of $47.6 million for Q1 2026, up from $27.1 million a year prior, primarily due to increased spending on its Viaskin Peanut patch development and commercial preparations. The company's cash and cash equivalents, boosted by recent financing and warrant exercises, stood at $229.2 million by March 31, 2026, which management expects to fund operations until Q2 2027. This increased expenditure is focused on clinical trials, pre-commercial inventory, and building out U.S. infrastructure for the anticipated Biologics License Application (BLA) submission for Viaskin Peanut in children aged 4 to 7 in the first half of 2026.
MAY 1·Stock Titan→
DBV Technologies (DBVT) ramps Q1 2026 spending but extends cash runway
DBV Technologies reported a wider net loss of $47.6 million in Q1 2026 due to increased spending on R&D, sales, and marketing as it prepares for the potential commercialization of its VIASKIN Peanut patch. Despite the larger loss, the net loss per share improved to $(0.11) thanks to a strengthened equity base from prior financings. The company ended the quarter with $229 million in cash and equivalents, which is expected to fund operations into Q2 2027, allowing continued pursuit of regulatory milestones and a new infant study.
